Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis
出版年份 2022 全文链接
标题
Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis
作者
关键词
-
出版物
CLINICAL AND EXPERIMENTAL MEDICINE
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-03-19
DOI
10.1007/s10238-022-00814-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
- (2021) Nandini Dey et al. Cancers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
- (2021) Francesco Schettini et al. Cancers
- LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
- (2021) S.A. Hurvitz et al. ANNALS OF ONCOLOGY
- Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
- (2020) Qamar J. Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer
- (2020) Jinming Li et al. JAMA Network Open
- Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis
- (2019) Tingting Zhang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
- (2019) Qianqian Guo et al. Targeted Oncology
- Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
- (2019) Lorenzo Rossi et al. Clinical Breast Cancer
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
- (2019) Sara A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
- (2019) Aleix Prat et al. LANCET ONCOLOGY
- Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
- (2018) Rajeev Ayyagari et al. CURRENT MEDICAL RESEARCH AND OPINION
- Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
- (2018) Luca Gianni et al. LANCET ONCOLOGY
- CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
- (2018) Carlo Messina et al. BREAST CANCER RESEARCH AND TREATMENT
- CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?
- (2018) M Brandão et al. ANNALS OF ONCOLOGY
- Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
- (2018) P Cottu et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
- (2018) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
- (2017) Louis W C Chow et al. ENDOCRINE-RELATED CANCER
- The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis
- (2017) Xianyu Chen et al. Future Oncology
- Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis
- (2017) Lun Li et al. Future Oncology
- Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer
- (2017) Miaomiao Tao et al. MEDICINE
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
- (2016) G. Curigliano et al. BREAST
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
- (2016) Laura M. Spring et al. JAMA Oncology
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- The Role of CDK4/6 Inhibition in Breast Cancer
- (2015) C. G. Murphy et al. ONCOLOGIST
- Control of cell cycle transcription during G1 and S phases
- (2013) Cosetta Bertoli et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
- (2012) E. Alba et al. ANNALS OF ONCOLOGY
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
- (2012) Nehmat Houssami et al. EUROPEAN JOURNAL OF CANCER
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial
- (2009) John A. Olson et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search